
Medtronic

HawkOne[™] Directional Atherectomy System




One device for above and below the knee

Treat all morphologies

- Consistent and predictable cutting
- Treats all lesion morphologies, from soft to severely calcified

Treat with procedural efficiency

- No capital equipment provides easy setup



• Simplified directional atherectomy selection with 6 F and 7 F HawkOne devices

Versatility above and below the knee

The HawkOne platform offers control and enhanced cutting to target and debulk all morphologies to gain lumen, prepare the vessel, and treat calcified lesions.



HawkOne directional atherectomy system¹⁻⁵

Treatment goal	Lesion morphology	Plaque distribution
Achieve lumen gain	Treat severe calcium	Target eccentric lesions
Create a channel	Treat soft plaque	Target concentric lesions

	Model name	Catalog number	Vessel diameter (mm)	Sheath compatibility (Fr)	Crossing profile (mm)	Working length‡	Effective length [§]	Tip length (cm)	Max. cut length (mm)	Packing device
7 F	LS	H1-LS	3.5-7.0	7	2.6	114	107	6.6	50	
	LX	H1-LX	3.5-7.0	7	2.6	114	104	9.6	75	
6 F	м	H1-M	3.0-7.0	6	2.2	135	129	5.9	40	
	S	H1-S	2.0-4.0	6	2.2	151	145	5.9	40	

Max guidewire is 0.014" for HawkOne devices.

⁺HawkOne working length – distal end of pre-loaded flush tool, in the proximal position, to the distal end of tip.

[§] HawkOne effective length – end of pre-loaded flush tool, in the proximal position, to the proximal end of cutter window.

¹ Aboufakher R, Torey J, Szpunar S, Davis T. Peripheral plaque volume changes pre- and post-rotational atherectomy followed by directional plaque excision: assessment by intravascular ultrasound and virtual histology. *J Invasive Cardiol*. October 2009;21(10):501-505.

² McKinsey J, Zellar T, Rocha-Singh KJ, Jaff MR, Garcia LA, DEFINITIVE LE Investigators. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. *JACC Cardiovasc Interv.* August 2014;7(8):923-933.

³ Roberts D, Niazi K, Miller W, et al. Effective endovascular treatment of calcified femoropopliteal disease with directional atherectomy and distal embolic protection: final results of the DEFINITIVE Ca++ trial. *Catheter Cardiovasc Interv.* August 1, 2014;84(2):236-244.

⁴ Bench data on file.

⁵ See Instructions for Use.

Important information

Indications, contraindications, warnings, and instructions for use can be found in the product labeling supplied with each device.

CAUTION: Federal (USA) law restricts these devices to sale by or on the order of a physician.

medtronic.com/hawkone

UC202302042 EN ©2022 Medtronic. Medtronic, Medtronic logo are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. For distribution in the USA only. 12/2022

Medtronic